Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
AssigneeAllergan Sales, Inc.
InventorsPatrick M. Hughes, Orest Olejnik
Life of this patent
Estimating the term…
Abstract
Pharmaceutical conjugates comprising a therapeutic component and an efficacy enhancing component that enhances the pharmacokinetic disposition of the therapeutic component is disclosed. In one embodiment, therapeutic component is joined to an efficacy enhancing component by a linker. In one embodiment, the therapeutic component and the efficacy enhancing component disassociate under physiolocal conditions, preferably near the site where the therapeutic component may exert a therapeutic effect.
Claims23
A pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula A:
- 8
- wherein X is
- 9
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker.
A pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula A:
- 11
- wherein X is
- 12
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker;
- the linker is selected from the group consisting of:
- 13
- wherein R12 is an H or a C1-C10 hydrocarbon, m=0 to 25 10, and n=0 to 10.
A method for treating an ophthalmic condition, the method comprising the step of administering a pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula I:
- 14
- wherein X is an H or a
- 15
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker.
Dependencies are inferred from the claim text.